Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE